ABIO ARCA biopharma, Inc. Stock Quote

ABIO [NASD]

Index	-	P/E	-	EPS (ttm)	-2.43	Insider Own	0.20%	Shs Outstand	9.38M	Perf Week	-7.44%
Market Cap	48.99M	Forward P/E	-	EPS next Y	-	Insider Trans	52.19%	Shs Float	9.28M	Perf Month	-19.04%
Income	-9.70M	PEG	-	EPS next Q	-	Inst Own	5.70%	Short Float	5.07%	Perf Quarter	-25.00%
Sales	-	P/S	-	EPS this Y	50.20%	Inst Trans	4.66%	Short Ratio	0.46	Perf Half Y	-19.23%
Book/sh	4.96	P/B	0.68	EPS next Y	-	ROA	-32.10%	Target Price	-	Perf Year	-30.86%
Cash/sh	3.37	P/C	1.00	EPS next 5Y	-	ROE	-34.30%	52W Range	3.20 - 22.00	Perf YTD	-16.21%
Dividend	-	P/FCF	-	EPS past 5Y	42.50%	ROI	-	52W High	-84.73%	Beta	2.74
Dividend %	-	Quick Ratio	14.30	Sales past 5Y	-	Gross Margin	-	52W Low	5.00%	ATR	0.19
Employees	11	Current Ratio	14.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	32.27	Volatility	4.69% 5.55%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	28.80%	Profit Margin	-	Rel Volume	0.43	Prev Close	3.40
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.02M	Price	3.36
Recom	-	SMA20	-9.35%	SMA50	-20.17%	SMA200	-29.35%	Volume	433,336	Change	-1.18%

Feb-27-18

Initiated

Ascendiant Capital Markets

Buy

Oct-09-13

Initiated

Dawson James

Buy

$3.75

Mar-18-21 04:30PM	ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update GlobeNewswire
Feb-13-21 01:09AM	Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation Simply Wall St.
Dec-15-20 08:30AM	ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 GlobeNewswire
Dec-09-20 05:40PM	ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders GlobeNewswire
Nov-23-20 12:28PM	ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment MarketWatch +7.46%
08:30AM	AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation GlobeNewswire
Nov-02-20 08:30AM	ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +5.19%
Oct-07-20 08:30AM	ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 GlobeNewswire -8.49%
Oct-05-20 04:30PM	ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality GlobeNewswire
Sep-21-20 08:00AM	ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19 GlobeNewswire -10.62%
Aug-17-20 08:49AM	We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth Simply Wall St.
Aug-12-20 08:00AM	ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19 ACCESSWIRE -7.51%
Aug-05-20 04:15PM	Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Jul-07-20 08:30AM	SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators GlobeNewswire
Jun-03-20 09:56AM	ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering GlobeNewswire -5.39%
09:56AM	Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More Zacks
Jun-01-20 08:20AM	ARCA Biopharma Announces $9.4 Million Registered Direct Offering GlobeNewswire -26.98%
May-29-20 12:24PM	A Mighty May: Over $200,000 In Gross Profits Benzinga -34.41%
09:59AM	Company News for May 29, 2020 Zacks
May-28-20 04:19PM	Arca Biopharma Nearly Quintuples On Plans To Test A Coronavirus Drug Investor's Business Daily +386.33%
12:14PM	Arca Biopharma Stock Triples On Plans To Test A Coronavirus Treatment Investor's Business Daily
10:27AM	Price Over Earnings Overview: ARCA biopharma Benzinga
08:00AM	ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy GlobeNewswire
May-07-20 08:30AM	Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions GlobeNewswire
May-06-20 04:30PM	ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update GlobeNewswire
Feb-18-20 04:30PM	ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
Feb-01-20 08:31AM	Does Market Volatility Impact ARCA biopharma, Inc.'s (NASDAQ:ABIO) Share Price? Simply Wall St.
Nov-06-19 04:10PM	ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-03-19 08:47AM	Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Invest In Growth? Simply Wall St.
Sep-12-19 08:30AM	ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium GlobeNewswire
Sep-11-19 08:30AM	Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting GlobeNewswire +13.16%
Sep-04-19 01:37PM	Could The ARCA biopharma, Inc. (NASDAQ:ABIO) Ownership Structure Tell Us Something Useful? Simply Wall St.
Aug-21-19 09:49AM	INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire +8.08%
Aug-01-19 04:30PM	ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire -7.30%
Jun-04-19 07:09AM	One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price Simply Wall St.
May-13-19 09:00AM	ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure GlobeNewswire -10.00%
May-08-19 04:30PM	ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire +20.03%
May-01-19 08:30AM	GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure GlobeNewswire +98.64%
Apr-23-19 08:30AM	ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial GlobeNewswire
Mar-18-19 08:30AM	Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology GlobeNewswire
Mar-06-19 08:00AM	Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine GlobeNewswire
Feb-27-19 04:15PM	ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-20-19 07:30AM	ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug GlobeNewswire +31.27%
Jan-16-19 08:30AM	Zosano Appoints Linda Grais M.D., J.D. to Board of Directors GlobeNewswire
Dec-26-18 11:47AM	ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling Simply Wall St. -7.06%
Dec-20-18 04:01PM	ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial GlobeNewswire -25.26%
Nov-14-18 04:30PM	ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire -6.94%
Nov-12-18 08:30AM	GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions GlobeNewswire
Nov-05-18 08:30AM	ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions GlobeNewswire +13.17%
Oct-10-18 04:16PM	Westminster biotech company receives second extension on delisting notice from Nasdaq American City Business Journals -5.43%
Oct-02-18 08:00AM	Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics ACCESSWIRE -35.29%
Sep-18-18 08:30AM	ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial GlobeNewswire
Aug-09-18 04:15PM	ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-18 09:45AM	Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018 ACCESSWIRE
Jul-31-18 12:15PM	3 Biotech Stocks in Focus on Tuesday ACCESSWIRE
08:30AM	ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation GlobeNewswire
08:10AM	Todays Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma ACCESSWIRE
Jun-19-18 07:05AM	Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks ACCESSWIRE
May-29-18 08:30AM	GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress GlobeNewswire
May-11-18 08:20AM	Todays Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma ACCESSWIRE
May-10-18 08:30AM	ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress GlobeNewswire
07:15AM	Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks ACCESSWIRE
May-08-18 04:15PM	ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update GlobeNewswire
Apr-23-18 08:30AM	ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement GlobeNewswire
Apr-03-18 07:20AM	Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease ACCESSWIRE
Mar-22-18 04:30PM	ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
Feb-27-18 03:00PM	Heres Why Arca Biopharma Inc (ABIO) Shares Are Skyrocketing Today SmarterAnalyst
Feb-26-18 02:18PM	ARCA biopharma And ObsEva Just Put Out Clinical Trial Data Market Exclusive
08:00AM	ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial GlobeNewswire
Jan-23-18 05:13PM	One Thing To Consider Before Buying ARCA biopharma Inc (NASDAQ:ABIO) Simply Wall St.
Jan-08-18 08:30AM	ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial GlobeNewswire
Jan-02-18 05:09PM	What You Must Know About ARCA biopharma Incs (NASDAQ:ABIO) Major Investors Simply Wall St.
Dec-08-17 06:13PM	Interested In Healthcare? Why ARCA biopharma Inc (ABIO) May Be The Entry Point Simply Wall St.
Nov-30-17 02:25PM	How Much is ARCA biopharma Incs (ABIO) CEO Getting Paid? Simply Wall St.
Nov-20-17 08:05AM	ARCA Biopharma, European Patent for Gencaro and Q3 Review ACCESSWIRE
Nov-17-17 08:10AM	Todays Research Reports on Stocks to Watch: ARCA biopharma and Amicus Therapeutics ACCESSWIRE
Nov-16-17 08:30AM	ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting GlobeNewswire
Nov-09-17 04:05PM	ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Oct-23-17 08:16PM	ARCA biopharma Inc (ABIO): How Does It Impact Your Portfolio? Simply Wall St.
Sep-21-17 08:30AM	ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference GlobeNewswire
Aug-16-17 08:30AM	ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial GlobeNewswire
Aug-09-17 04:30PM	ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis GlobeNewswire
Aug-03-17 04:15PM	ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Jun-20-17 08:30AM	ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis DSMB Recommendation Anticipated in August 2017 GlobeNewswire
May-15-17 08:30AM	ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Apr-26-17 08:30AM	ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial Business Wire
Apr-18-17 08:30AM	ARCA biopharma to Present at the Planet MicroCap Showcase 2017 Investor Conference Business Wire
Mar-25-17 01:04PM	ARCA BIOPHARMA, INC. Financials
Mar-21-17 04:46PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
04:30PM	ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update Business Wire
04:10PM	ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report
Mar-06-17 04:32PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM	ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Mar-01-17 04:47PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-21-17 08:46AM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
08:30AM	Anders Hove, MD Joins ARCA biopharma Board of Directors Business Wire
Jan-18-17 04:32PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM	ARCA biopharma Announces 150th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Business Wire
Jan-11-17 04:54PM	ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit
Jan-04-17 08:30AM	ARCA biopharma to Present at Biotech Showcase 2017 Business Wire

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CONWAY ROBERT E	Chairman of the Board	Dec 18	Buy	4.16	10,000	41,630	30,000	Dec 21 04:15 PM
CONWAY ROBERT E	Chairman of the Board	Sep 25	Buy	4.28	5,000	21,399	20,000	Sep 25 04:20 PM
CONWAY ROBERT E	Chairman of the Board	Sep 22	Buy	4.66	3,056	14,241	15,000	Sep 24 04:20 PM
CONWAY ROBERT E	Chairman of the Board	Sep 21	Buy	4.77	10,000	47,660	11,944	Sep 21 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience